121 related articles for article (PubMed ID: 25541745)
1. Investigation of the N-BP Binding at FPPS by Combined Computational Approaches.
Stefanucci A; Marrone A; Agamennone M
Med Chem; 2015; 11(5):417-31. PubMed ID: 25541745
[TBL] [Abstract][Full Text] [Related]
2. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR, molecular docking, and ONIOM studies on the structure-activity relationships and action mechanism of nitrogen-containing bisphosphonates.
Liu QZ; Wang SS; Li X; Zhao XY; Li K; Lv GC; Qiu L; Lin JG
Chem Biol Drug Des; 2018 Mar; 91(3):735-746. PubMed ID: 29080272
[TBL] [Abstract][Full Text] [Related]
4. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase.
Ohno K; Mori K; Orita M; Takeuchi M
Curr Med Chem; 2011; 18(2):220-33. PubMed ID: 21110804
[TBL] [Abstract][Full Text] [Related]
5. Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer.
Huang CH; Gabelli SB; Oldfield E; Amzel LM
Proteins; 2010 Mar; 78(4):888-99. PubMed ID: 19876942
[TBL] [Abstract][Full Text] [Related]
6. Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase.
Park J; Rodionov D; De Schutter JW; Lin YS; Tsantrizos YS; Berghuis AM
PLoS One; 2017; 12(10):e0186447. PubMed ID: 29036218
[TBL] [Abstract][Full Text] [Related]
7. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.
Tsoumpra MK; Muniz JR; Barnett BL; Kwaasi AA; Pilka ES; Kavanagh KL; Evdokimov A; Walter RL; Von Delft F; Ebetino FH; Oppermann U; Russell RGG; Dunford JE
Bone; 2015 Dec; 81():478-486. PubMed ID: 26318908
[TBL] [Abstract][Full Text] [Related]
9. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
Räikkönen J; Taskinen M; Dunford JE; Mönkkönen H; Auriola S; Mönkkönen J
Biochem Biophys Res Commun; 2011 Apr; 407(4):663-7. PubMed ID: 21420384
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
11. Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.
Gritzalis D; Park J; Chiu W; Cho H; Lin YS; De Schutter JW; Lacbay CM; Zielinski M; Berghuis AM; Tsantrizos YS
Bioorg Med Chem Lett; 2015 Mar; 25(5):1117-23. PubMed ID: 25630225
[TBL] [Abstract][Full Text] [Related]
12. NMR for screening and a biochemical assay: Identification of new FPPS inhibitors exerting anticancer activity.
Grimaldi M; Randino R; Ciaglia E; Scrima M; Buonocore M; Stillitano I; Abate M; Covelli V; Tosco A; Gazzerro P; Bifulco M; Rodriquez M; D'Ursi AM
Bioorg Chem; 2020 May; 98():103449. PubMed ID: 32057422
[TBL] [Abstract][Full Text] [Related]
13. Thermodynamic evaluation of the binding of bisphosphonates to human farnesyl pyrophosphate synthase.
Kawasaki Y; Sekiguchi M; Kawasaki M; Hirakura Y
Chem Pharm Bull (Tokyo); 2014; 62(1):77-83. PubMed ID: 24172032
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
[TBL] [Abstract][Full Text] [Related]
15. Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010).
Sun S; McKenna CE
Expert Opin Ther Pat; 2011 Sep; 21(9):1433-51. PubMed ID: 21702715
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors.
Liu Q; Miao Y; Wang X; Lv G; Peng Y; Li K; Li M; Qiu L; Lin J
Eur J Med Chem; 2020 Jan; 186():111905. PubMed ID: 31785819
[TBL] [Abstract][Full Text] [Related]
17. Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates.
Aripirala S; Gonzalez-Pacanowska D; Oldfield E; Kaiser M; Amzel LM; Gabelli SB
Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):802-10. PubMed ID: 24598749
[TBL] [Abstract][Full Text] [Related]
18. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
19. Crystallization and preliminary neutron diffraction experiment of human farnesyl pyrophosphate synthase complexed with risedronate.
Yokoyama T; Ostermann A; Mizuguchi M; Niimura N; Schrader TE; Tanaka I
Acta Crystallogr F Struct Biol Commun; 2014 Apr; 70(Pt 4):470-2. PubMed ID: 24699741
[TBL] [Abstract][Full Text] [Related]
20. Human farnesyl pyrophosphate synthase inhibition by nitrogen bisphosphonates: a 3D-QSAR study.
Fernández D; Ortega-Castro J; Frau J
J Comput Aided Mol Des; 2013 Aug; 27(8):739-54. PubMed ID: 23979193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
